Featured Speakers of 2012

• 

  Allan ClarkeDirector, Formulation, Process & Analysis GSK

• 

  John FlygareSenior Scientist Genentech

• 

  Susan AshwellDirector, Cancer Chemistry AstraZeneca

• 

  Anthony Schatz Senior Principal Scientist Merck

Cytotoxic Drug Development is Entering a New Era…

Novel agents, newly emerging delivery methods and innovations in payload chemistry are all contributing to dramatically increasing the therapeutic window for cytotoxics. With new drugs overcoming many of the hurdles faced by early cytotoxics such as reducing adverse effects and shortening administration times, the industry still faces great challenges in increasing efficacy, safety and tackling resistance.

Now is the time to move forward into the next generation of anti-cancer drugs…

We will be releasing the draft agenda for the 2nd Annual Novel Cytotoxic Drugs meeting very soon. Taking place in Washington D.C. in April 2013, this gathering will build upon the success of our 2012 conference.

On the 28th - 30th March 2012, we ran our inaugural Novel Cytotoxic Drugs meeting, where the issues associated with developing cytotoxics were tackled head on with open discussions, practical case studies and interactive workshops.

Hear what attendees said about the meeting:

“Well run and educational – I’m glad I came!”David Pauling, IP Counsel, Sutro Biopharma

"The topics were informative and brought together leaders in the field for a sharing of opinions and results”Chris Verbicky, Director, Coldstream Labs

“The organisation of this meeting was exemplary, very effective”Alexei Bashakian, Professor, University Arkansas“I think that Hanson Wade put on a very professional, scientific, well organised and pleasant meeting that encouraged positive networking. I loved the speed networking and mastermind groups.” Tony Schatz, Senior Principal Scientist, Merck

Bringing together pharma, biotechs, and academic leaders as well as contract manufacturers and handling experts, the 2nd Annual Novel Cytotoxic Drugs will once again provide an opportunity for you to benchmark your company against leaders in the cytotoxic field. Focusing on tumor targeting, drug administration and regulatory issues, the next meeting will help you to identify the steps you need to take to achieve clinical success.

Attendees at the 2012 meeting:

• Explored how to improve tumour delivery and reduce side effects through case studies on targeting cytotoxic agents from Genentech, Endocyte and Immunogen
• Identified the steps needed to take to develop promising potent agents by learning from Spirogen’s preclinical and clinical experience
• Found out how to improve the manufacturability of their highly potent drug by hearing how GSK have been doing it
• Discovered the best methods of tackling cross contamination issues and third party manufacturing strategies with case studies from Merck
• Gained an update from leading academics at  Stony Brook University University, Maryland Greenebaum Cancer University and Arkansas Medical Sciences on identifying and developing the next generation of Taxoids and Endonucleases
• Learned to manage their IP portfolio and maximize value from their innovation by attending the workshop on discovery, development, and commercialization projects of cytotoxic products  

Who attended? 

Novel Cytotoxic Drugs focused on how to develop and manufacture these anti cancer drugs. This meant it was for:

• Pharma companies focusing on developing potent, novel cancer therapeutics
• Scientists working in chemistry, HPAPI development and medical chemistry
• Biotechs working on novel payload discovery and other exciting small molecule compounds
• Companies pioneering new delivery mechanisms for targeting cancer payloads
• CMOs looking to partner with drug developers
• Equipment and Handling Solution Providers specialising in dealing with these potent compounds

What's next? 

1. Look out for the draft agenda for the Novel Cytotoxic Drugs 2013 meeting - we will be releasing it soon
2. Something you want to share; white papers or articles? Then let us know... just email any questions to info@hansonwade.com
3. Don't waste time! If you're planning on joining us then get the best rates by securing your place for the 2013 meeting now - Book online or call +1 212 537 5898